Advancing ALK+ NSCLC Care: Optimizing Treatment, Sequencing, and Long-Term Outcomes

Ryan Haumschild, PharmD, MS, MBA, CPEL; Elizabeth Castronovo, NP; Martin Dietrich, MD, PhD; Mary Grizzard MSN, FNP, and Christine M. Lovly, MD, PhD, FASCO discuss how advances in ALK+ NSCLC treatment, including 5-year CROWN trial data for lorlatinib, recent ensartinib approval, comparative efficacy against brain metastases, toxicity management strategies, and sequencing approaches following progression, are reshaping clinical decision-making to optimize long-term patient outcomes.